Arrowhead Pharmaceuticals, Inc.

Stocks

ARWR

US04280A1007

Real-time Estimate Cboe BZX Other stock markets 15:48:08 15/06/2026 BST			5-day change	1st Jan Change
76.71 ^USD	+2.94%		+3.91%	+15.60%

06-10	Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 07:58 AM
05-27	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	CI

Transcript : Arrowhead Pharmaceuticals, Inc., Q2 2026 Earnings Call, May 07, 2026

Published on 05/08/2026 at 04:05 am BST - Modified on 05/25/2026 at 06:08 pm BST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, welcome to the Arrowhead Pharmaceuticals Conference Call. [Operator Instructions]

I will now hand

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Arrowhead Pharmaceuticals, Inc.

06-10	Arrowhead Pharmaceuticals, Inc. Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026, Jun-10-2026 07:58 AM
05-27	Arrowhead Pharmaceuticals Presents New Clinical Data on RNAi-based Obesity and MASH Candidate ARO-INHBE at EASL 2026	CI
05-26	Arrowhead Pharmaceuticals Presents New Positive Clinical Data for Plozasiran at the 94th European Atherosclerosis Society Congress	CI
05-15	Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Global Healthcare Conference 2026, May-12-2026 through May-14-2026
05-08	RBC Capital Adjusts Arrowhead Pharmaceuticals Price Target to $87 From $80, Maintains Outperform Speculative Risk Rating	MT
05-08	Arrowhead Pharmaceuticals, Inc., Q2 2026 Earnings Call, May 07, 2026
05-07	Arrowhead Pharmaceuticals Swings to Fiscal Q2 Loss, Revenue Falls	MT
05-07	Earnings Flash (ARWR) Arrowhead Pharmaceuticals Posts Q2 Loss $0.93, vs. FactSet Est of $1.10 Loss	MT
05-07	Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2026	CI
05-07	Earnings Flash (ARWR) Arrowhead Pharmaceuticals, Inc. Reports Q2 Revenue $73.7M, vs. FactSet Est of $73.8M	MT
05-05	Arrowhead Signs Deal With Madrigal to License Clinical MASH Program	MT
05-05	Arrowhead Pharmaceuticals - licenses Aro-Pnpla3 to Madrigal Pharmaceuticals	RE
05-05	Arrowhead Pharmaceuticals Announces Exclusive Worldwide License Agreement with Madrigal Pharmaceuticals for ARO-PNPLA3	CI
05-01	Arrowhead Pharmaceuticals Inc Receives Tga Approval of Redemplo in Australia Expanding Global Access for Patients with Familial Chylomicronemia Syndrome	CI
05-01	JPMorgan Initiates Arrowhead Pharmaceuticals at Overweight With $88 Price Target	MT